Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin

There is an urgent need for new antituberculosis (anti-TB) drugs, including agents that are safe and effective with concomitant antiretrovirals (ARV) and first-line TB drugs. PA-824 is a novel antituberculosis nitroimidazole in late-phase clinical development. Cytochrome P450 (CYP) 3A, which can be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dooley, Kelly E., Luetkemeyer, Anne F., Park, Jeong-Gun, Allen, Reena, Cramer, Yoninah, Murray, Stephen, Sutherland, Deborah, Aweeka, Francesca, Koletar, Susan L., Marzan, Florence, Bao, Jing, Savic, Rada, Haas, David W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4135849/
https://ncbi.nlm.nih.gov/pubmed/24957823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03332-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados